Dr Nicole Campbell is a member of the Regulation of Interferon and Innate Signalling Research group in the Centre for Innate Immunity and Infectious Diseases.
Areas of interest
Dr Campbell leads efforts within Prof Hertzog’s lab to characterise the immunoregulatory functions of interferon epsilon in the peritoneal cavity, and its potential as a novel therapy for ovarian cancer.
A senior postdoctoral researcher working on the immunomodulatory properties of type I interferons, Dr Campbell’s current research is centered on interferon epsilon – a unique type I interferon discovered by Prof Paul Hertzog’s laboratory at Hudson Institute, which is constitutively expressed under hormonal control in the female reproductive tract.
Dr Campbell obtained her PhD in Immunology at Trinity College Dublin, Ireland in 2018, where she studied the anti-inflammatory functions of the enzyme heme oxygenase 1. In 2019 she joined the laboratory of Prof Paul Hertzog at Hudson Institute, where she has since led studies on interferon epsilon in ovarian cancer, interferon signalling dynamics, and the innate immune response to COVID-19.
In 2023 Dr Campbell was selected as one of six Hudson Institute Emerging Leaders, and awarded a Pilot Award from the United States Department of Defense Ovarian Cancer Research Program worth over $500,000 (AUD).